ファイザー製トランプ汁接種 抗体だけでなく、T細胞免疫も4か月後に大きく低下

 

Diminishing immune responses against variants of concern in dialysis patients four months after SARS-CoV-2 mRNA vaccination

Abstract

Patients undergoing chronic hemodialysis were among the first to receive SARS-CoV-2 vaccinations due to their increased risk for severe COVID-19 disease and high case fatality rates. To date, there have been minimal longitudinal studies in hemodialysis patients to ascertain whether protection offered by vaccination is long-lasting. To assess how surrogates for protection changed over time, we examined both the humoral and cellular response in a previously reported cohort of at-risk hemodialysis patients and healthy donors, four months after their second dose of Pfizer BNT162b2. Compared to three weeks post-second vaccination, both cellular and humoral responses against the original SARS-CoV-2 isolate as well as variants of concern were significantly reduced, with some dialyzed individuals having no B- or T-cell response. Our data strongly support the need for a third booster in hemodialysis patients and potentially other at-risk individuals.

https://www.medrxiv.org/content/10.1101/2021.08.16.21262115v1

最低でも年三回。（爆ｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗ 

もうイスラエルはアウト確定でしょうな。（爆ｗｗｗｗｗｗｗｗｗｗｗｗｗｗ